Therapeutic Drug Monitoring of Tildrakizumab in Psoriasis Patients

Launched by UNIVERSITY HOSPITAL, GHENT · Jan 5, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a medication called tildrakizumab, which is used to treat moderate to severe psoriasis, a skin condition that causes red, scaly patches. The researchers want to find out if measuring the levels of tildrakizumab in the blood early on can help determine the best dose for each patient, rather than using a one-size-fits-all approach. This could help avoid giving too much or too little of the medication, making treatment more effective and potentially less expensive.

To be eligible for this study, participants need to have a specific type of psoriasis called chronic plaque-type psoriasis, and they must be willing to sign a consent form that explains the study. Participants who are pregnant, breastfeeding, or have a different form of psoriasis cannot join. Those who take part will undergo a few blood tests to measure the medication levels and will help researchers understand how to use this treatment better. This research is important because it could lead to improved care for psoriasis patients in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Participants must have a clinical or histological diagnosis of chronic plaque-type psoriasis
• • Participants must sign an ICF indicating that he or she understands the purpose of, and procedures required for, the study and is willing to participate in the study
• Exclusion Criteria:
• • Participants who have currently a predominant nonplaque form of psoriasis
• • Participants who are pregnant, nursing or planning a pregnancy
• • Participants who are unable or unwilling to undergo multiple venapunctures
• • Participants who are treated according to a different dosing schedule than standard dosing of tildrakizumab

Trial Officials